Bio News
Biohaven will sell the rights to the advanced epilepsy drug opicapone to South Korea’s SK Biopharmaceuticals for up to $795 million. SK Biopharmaceuticals will pay $350 million upfront and $50 million next year, with up to an additional $150 million upon achieving development and regulatory milestones. If opicapone is approved, Biohaven will receive royalties in the mid-teens to low 20% range.
BIOBOOK TEAM
biobookmedia@biobook.co.krAsahi Kasei Wins FDA Approval for New Herpes Drug Hovlpri for Immunocompromised Adults
Mirum’s Livmarli succeeds in phase 3 trial, company seeks expanded indication for rare liver disease
Roche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
